Provention Bio, Inc. (NASDAQ:PRVB) Stock Holdings Increased by Swiss National Bank

Swiss National Bank raised its holdings in shares of Provention Bio, Inc. (NASDAQ:PRVB – Get Rating) by 47.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,100 shares of the company’s stock after acquiring an additional 60,200 shares during the period. Swiss National Bank owned approximately 0.21% of Provention Bio worth $1,978,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Cabot Wealth Management Inc. bought a new stake in Provention Bio during the 4th quarter valued at $1,948,000. Bioimpact Capital LLC raised its stake in shares of Provention Bio by 25.0% in the 3rd quarter. Bioimpact Capital LLC now owns 740,344 shares of the company’s stock worth $3,332,000 after buying an additional 147,909 shares in the last quarter. Parallax Volatility Advisers L.P. raised its stake in shares of Provention Bio by 8.9% in the 3rd quarter. Parallax Volatility Advisers L.P. now owns 16,122 shares of the company’s stock worth $73,000 after buying an additional 1,322 shares in the last quarter. Raymond James & Associates raised its stake in shares of Provention Bio by 44.1% in the 3rd quarter. Raymond James & Associates now owns 18,482 shares of the company’s stock worth $83,000 after buying an additional 5,652 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in shares of Provention Bio by 47.8% in the 4th quarter. Arizona State Retirement System now owns 21,860 shares of the company’s stock worth $231,000 after buying an additional 7,068 shares in the last quarter. Institutional investors own 37.39% of the company’s stock.

Provention Bio Stock Performance

Shares of PRVB stock opened at $24.98 on Friday. Provention Bio, Inc. has a 1-year low of $3.18 and a 1-year high of $25.00. The company has a current ratio of 1.93, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of -16.33 and a beta of 2.47. The stock’s fifty day simple moving average is $24.52 and its 200-day simple moving average is $14.74.

Provention Bio (NASDAQ:PRVB – Get Rating) last issued its earnings results on Wednesday, March 29th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). Provention Bio had a negative net margin of 880.69% and a negative return on equity of 103.36%. The firm had revenue of $10.81 million during the quarter, compared to analysts’ expectations of $7.23 million. On average, sell-side analysts predict that Provention Bio, Inc. will post -1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Provention Bio

In other Provention Bio news, major shareholder Sessa Capital (Master), L.P. sold 2,190,549 shares of the business’s stock in a transaction dated Friday, April 14th. The stock was sold at an average price of $24.32, for a total value of $53,274,151.68. Following the transaction, the insider now owns 15,567,497 shares in the company, valued at $378,601,527.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PRVB shares. Jefferies Financial Group downgraded Provention Bio from a “buy” rating to a “hold” rating and set a $25.00 price objective on the stock. in a research note on Tuesday, March 14th. Chardan Capital decreased their target price on Provention Bio from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, March 13th. Sumitomo Mitsui Financial Group restated a “neutral” rating and issued a $25.00 target price (up from $15.00) on shares of Provention Bio in a report on Tuesday, March 14th. Cantor Fitzgerald cut Provention Bio from an “overweight” rating to a “neutral” rating in a report on Monday, March 13th. Finally, HC Wainwright cut Provention Bio from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $16.00 to $25.00 in a report on Wednesday, March 15th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Provention Bio presently has an average rating of “Hold” and an average target price of $22.83.

Provention Bio Profile

(Get Rating)

Provention Bio, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset.